Julie L. Eiseman

4.3k total citations
131 papers, 3.5k citations indexed

About

Julie L. Eiseman is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Julie L. Eiseman has authored 131 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Molecular Biology, 44 papers in Oncology and 19 papers in Cancer Research. Recurrent topics in Julie L. Eiseman's work include Cancer therapeutics and mechanisms (27 papers), Cancer Treatment and Pharmacology (16 papers) and Drug Transport and Resistance Mechanisms (11 papers). Julie L. Eiseman is often cited by papers focused on Cancer therapeutics and mechanisms (27 papers), Cancer Treatment and Pharmacology (16 papers) and Drug Transport and Resistance Mechanisms (11 papers). Julie L. Eiseman collaborates with scholars based in United States, Canada and Netherlands. Julie L. Eiseman's co-authors include Merrill J. Egorin, Erin Joseph, Joseph M. Covey, Robert A. Parise, Dorothy L. Sentz, Alvito P. Alvares, Jan H. Beumer, Deborah R. Hamburger, Donald J. Creighton and Jianxia Guo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Julie L. Eiseman

130 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie L. Eiseman United States	34	2.1k	733	344	306	302	131	3.5k
Sushil Kumar India	22	1.8k 0.8×	793 1.1×	277 0.8×	378 1.2×	334 1.1×	67	3.4k
Bikul Das United States	23	1.6k 0.8×	922 1.3×	259 0.8×	391 1.3×	378 1.3×	54	3.3k
Natarajan Venkatesan United States	32	1.7k 0.8×	866 1.2×	159 0.5×	180 0.6×	115 0.4×	87	3.4k
Sibaji Sarkar United States	19	2.5k 1.2×	1.1k 1.5×	286 0.8×	349 1.1×	278 0.9×	47	4.0k
Mckenna Longacre United States	9	1.7k 0.8×	935 1.3×	256 0.7×	314 1.0×	196 0.6×	16	3.0k
K Lapińska United States	8	1.8k 0.9×	928 1.3×	254 0.7×	307 1.0×	198 0.7×	8	3.0k
Shannon Byler United States	7	1.8k 0.9×	971 1.3×	255 0.7×	319 1.0×	200 0.7×	9	3.0k
Heidi Wunderli‐Allenspach Switzerland	33	1.4k 0.7×	801 1.1×	248 0.7×	216 0.7×	259 0.9×	62	2.8k
Sarah Heerboth United States	11	2.0k 0.9×	983 1.3×	258 0.8×	318 1.0×	211 0.7×	14	3.2k
Paul M. Loadman United Kingdom	37	2.1k 1.0×	1.1k 1.5×	267 0.8×	410 1.3×	234 0.8×	152	4.0k

Countries citing papers authored by Julie L. Eiseman

Since Specialization

Citations

This map shows the geographic impact of Julie L. Eiseman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie L. Eiseman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie L. Eiseman more than expected).

Fields of papers citing papers by Julie L. Eiseman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie L. Eiseman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie L. Eiseman. The network helps show where Julie L. Eiseman may publish in the future.

Co-authorship network of co-authors of Julie L. Eiseman

This figure shows the co-authorship network connecting the top 25 collaborators of Julie L. Eiseman. A scholar is included among the top collaborators of Julie L. Eiseman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie L. Eiseman. Julie L. Eiseman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leibowitz, Brian J., Liheng Yang, Wei Liang, et al.. (2018). Targeting p53-dependent stem cell loss for intestinal chemoprotection. Science Translational Medicine. 10(427). 42 indexed citations

Sehrawat, Anuradha, Su‐Hyeong Kim, Eun‐Ryeong Hahm, et al.. (2016). Cancer‐selective death of human breast cancer cells by leelamine is mediated by bax and bak activation. Molecular Carcinogenesis. 56(2). 337–348. 18 indexed citations

Holleran, Julianne L., Julie L. Eiseman, Robert A. Parise, Shivaani Kummar, & Jan H. Beumer. (2016). LC–MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 129. 359–366. 9 indexed citations

Muzzio, Miguel, Julianne L. Holleran, Robert A. Parise, et al.. (2015). Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs. Cancer Chemotherapy and Pharmacology. 75(5). 1015–1023. 2 indexed citations

Appleman, Leonard J., Sanjeeve Balasubramaniam, Robert A. Parise, et al.. (2014). A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent. Clinical Cancer Research. 21(4). 721–729. 5 indexed citations

Parise, Robert A., Jan H. Beumer, Lora H. Rigatti, et al.. (2013). Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. Cancer Chemotherapy and Pharmacology. 72(6). 1195–1204. 6 indexed citations

LaValle, Courtney R., Liyong Zhang, Shuping Xu, Julie L. Eiseman, & Qiming J. Wang. (2012). Inducible Silencing of Protein Kinase D3 Inhibits Secretion of Tumor-Promoting Factors in Prostate Cancer. Molecular Cancer Therapeutics. 11(7). 1389–1399. 23 indexed citations

Parise, Robert A., et al.. (2012). Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines. Cancer Chemotherapy and Pharmacology. 71(1). 73–83. 4 indexed citations

Beumer, Jan H., Julie L. Eiseman, Judith A Gilbert, et al.. (2010). Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemotherapy and Pharmacology. 67(2). 421–430. 12 indexed citations

10.

Zamboni, William C., Julie L. Eiseman, Sandra Strychor, et al.. (2010). Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. Journal of Liposome Research. 21(1). 70–80. 23 indexed citations

11.

Eiseman, Julie L., Jianxia Guo, Ramesh K. Ramanathan, et al.. (2007). Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 13(7). 2121–2127. 10 indexed citations

12.

Kanick, Stephen C., Julie L. Eiseman, Erin Joseph, Jianxia Guo, & Robert S. Parker. (2007). Noninvasive and nondestructive optical spectroscopic measurement of motexafin gadolinium in mouse tissues: Comparison to high-performance liquid chromatography. Journal of Photochemistry and Photobiology B Biology. 88(2-3). 90–104. 9 indexed citations

13.

Florian, Jeffry, William C. Zamboni, Julie L. Eiseman, et al.. (2006). A physiologically-based pharmacokinetic (PBPK) model of docetaxel in SCID mice bearing SKOV3 human ovarian cancer xenografts. Cancer Research. 66. 730–730. 1 indexed citations

14.

Strychor, Sandra, Julie L. Eiseman, Erin Joseph, et al.. (2006). Plasma, tissue and tumor disposition of STEALTH® liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenografts. Cancer Research. 66. 721–721. 3 indexed citations

15.

Egorin, Merrill J., et al.. (1999). Plasma pharmacokinetics and tissue distribution in CD 2 F 1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent. Cancer Chemotherapy and Pharmacology. 44(4). 283–294. 25 indexed citations

16.

Eiseman, Julie L., et al.. (1994). Partial growth suppression of human prostate cancer cells by the Krev‐1 suppressor gene. The Prostate. 25(4). 177–188. 13 indexed citations

17.

Leslie, James, et al.. (1993). Stability problems with taxol in mouse plasma during analysis by liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis. 11(11-12). 1349–1352. 13 indexed citations

18.

Martin, Stephen J., Timothy P. O’Neill, John A. Bilello, & Julie L. Eiseman. (1991). Lymphocyte transformation abnormalities in bovine immunodeficiency-like virus infected calves. Immunology Letters. 27(2). 81–84. 40 indexed citations

19.

Eiseman, Julie L., Babette S. Zemel, Cathy A. Jenkins, & Carol M. Worthman. (1990). Physical growth and endocrine correlates of blood pressure variation among bundi gende speaking adolescents of papua new guinea. American Journal of Physical Anthropology. 81(2). 219. 2 indexed citations

20.

Eiseman, Julie L. & Alvito P. Alvares. (1978). Alterations Induced in Heme Pathway Enzymes and Monooxygenases by Gold. Molecular Pharmacology. 14(6). 1176–1188. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact